^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Dawn™

    Company:
    Intervenn Biosci
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    over2years
    InterVenn Biosciences announces new data validating the clinical performance of DAWN™ IO Melanoma as a novel liquid biopsy test to improve assessment of benefit to cancer patients (Businesswire)
    "InterVenn® Biosciences...announced new data showing that its new DAWN IO Melanoma test accurately assesses and classifies advanced melanoma patients as likely or unlikely to benefit from immune checkpoint inhibitor therapies: either pembrolizumab alone or ipilimumab in combination with nivolumab."
    Retrospective data
    |
    Dawn™